EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study

Anna Panovská, Pavel Žák iD, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2024. Verfasst von Anna Panovská und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Leukemia, Hairy Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EARTRIS-CZ, National Institute for Cancer Research (Program EXCELES), Czech CLL Study Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hairy cell leukemia (HCL) and HCL‐like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real‐world setting. We analyzed 225 HCL and 26 HCLv patients with median follow‐up of 67.9 months (HCL) and 20.1 months (HCLv). Median age at diagnosis was 56.2 (HCL) and 69.5 years (HCLv), male predominance was observed in both groups (76.0% vs. 73.1%). Diagnostics was mostly based on morphological evidence of hairy cells in the peripheral blood and bone marrow. At diagnosis, BRAF V6 00E mutation was detected in 94.7% of examined HCL patients and in no HCLv patient. Front‐line treatment was indicated in 205 (91.1%) HCL and 18 (69.2%) HCLv patients. The majority of HCL patients were administered a cladribine‐based regimen (91.2%). Overall response rate (ORR) was higher in cladribine‐treated patients compared to those given other treatments (97.7% vs. 81.3%), the same applied with achieving Complete remission (CR) (91.2% vs. 62.5%). HCLv treatment was heterogeneous, but cladribine remained the most frequent option (44.4%) with ORR 81.3% and CR rates 43.8%. Second‐line treatment was indicated in 52 HCL and 8 HCLv patients, 25.4% and 44.4% of those treated in first‐line. In the whole HCL group, median time to next treatment (TTNT) was not reached and 10‐year TTNT was estimated at 74.1%. HCLv patients who underwent first‐line treatment had a median TTNT of 56 months. The median overall survival (OS) in HCL patients was not reached compared to HCLv with a median OS of 9.5 years. These data confirm an excellent prognosis for HCL patients treated with cladribine‐based therapy. On the contrary, HCLv with its aggressive behavior represents a group of patients in whom novel treatment approaches are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Hairy CellHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAdultAged, 80 and overTreatment OutcomeCladribineFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

BRAF V600Emutationcladribinehairy cell leukemiahairy cell leukemia variantoverall survivaltime to next treatment

Substanzen

CladribineProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

ORCID-Profile: Pavel Žák, Michael Doubek

Förderung

  • EARTRIS-CZ
  • National Institute for Cancer Research (Program EXCELES)
  • Czech CLL Study Group

Zitieren

APA

Panovská, A., Žák, P., Jurková, T., Arpáš, T., Brychtová, Y., Vašíková, A., Hrabčáková, V., Prchlíková, A., Filipová, M., & Doubek, M. (2024). Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study. Hematological Oncology. https://doi.org/10.1002/hon.3280

Vancouver

Panovská A, Žák P, Jurková T, Arpáš T, Brychtová Y, Vašíková A, et al. Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study. Hematological Oncology. 2024. doi:10.1002/hon.3280

BibTeX
@article{Panovsk2024,
  author = {Panovská, Anna and Žák, Pavel and Jurková, Tereza and Arpáš, Tomáš and Brychtová, Yvona and Vašíková, Alžběta and Hrabčáková, Viera and Prchlíková, Adéla and Filipová, Martina and Doubek, Michael},
  title = {Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3280}
}
Kostenlos starten →